C-type natriuretic peptide and heart failure

Pharmacological Research

Volumn 54, Issue 5, 2006, Pages 326-333

  Del Ry, Silvia ^a   Passino, Claudio ^a   Emdin, Michele ^a   Giannessi, Daniela ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

C type natriuretic peptide; Chronic heart failure; Natriuretic peptide

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN CONVERTING ENZYME INHIBITOR; NATRIURETIC PEPTIDE TYPE C;

AUTOCRINE EFFECT; CARDIOVASCULAR FUNCTION; ENDOCRINE FUNCTION; EVALUATION; HEART FAILURE; HUMAN; MEDICAL LITERATURE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, C-TYPE;

EID: 33749523827     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.06.011     Document Type: Review

References (88)

1. De Bold A.J., Borenstein H.B., Veress A.T., and Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28 (1981) 89-94
2. Espiner E.A., Richards A.M., Yandle T.G., and Nicholls M.G. Natriuretic hormones. Endocrin Metab Clin North Am 24 (1995) 481-509
3. Suzuki T., Yamazaki T., and Yazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res 51 (2001) 489-494
4. D'Souza S.P., Davis M., and Baxter G.F. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharm Therap 101 (2004) 113-129
5. Baxter G.F. The natriuretic peptides. Basic Res Cardiol 99 (2004) 71-75
6. Inagami T. Atrial natriuretic factor as a volume regulator. J Clin Pharmacol 34 (1994) 424-426
7. Sagnella G.A. Measurement and significance of circulating natriuretic peptides in cardiovascular diseases. Clin Sci 95 (1998) 519-529
8. Ogawa Y., Nakao K., Mukoyama M., Hosoda K., Shirakami G., Arai H., et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res 69 (1991) 491-500
9. Clerico A., and Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 50 (2004) 33-50
10. Burnett J.C., Kao P.C., and Hu D.C. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231 (1986) 1145-1147
11. Mukoyama M., Nakao K., Hosoda K., Suga S., Saito Y., Ogawa Y., et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 (1991) 1402-1412
12. Schirger J.A., Heublein D.M., Chen H.H., Lisy O., Jougasaki M., Wennberg, et al. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase durino human heart failure. Mayo Clin Proc 74 (1999) 126-130
13. Schweitz H., Vigne P., Moinier D., Frelin C., and Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 267 (1992) 13928-13932
14. Best P.J., Burnett J.C., Wilson S.H., Holmes Jr. D.R., and Lerman A. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res 55 (2002) 375-384
15. Schulz-Knappe P., Forssmann K., Herbest F., Hock D., Pipkorn R., and Forssmann W.G. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 66 (1988) 752-759
16. Elsner D., Muders F., Munte A., Kromer E.P., Forssmann W.G., and Riegger G.A. Efficacy of prolonged infusion of urodilatin [ANP-(95-126)] in patients with congestive heart failure. Am Heart J 129 (1995) 766-773
17. Sudoh T., Minamino N., Kangawa K., and Matsuo H. C-type natriuretic peptide (CNP): a new member of the natriuretic peptide family identified in porcine brain. Biochem Biopys Res Commun 168 (1990) 863-870
18. Abassi Z., Karram T., Ellaham S., Winaver J., and Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharm Ther 102 (2004) 223-241
19. Barr C.S., Rhodes P., and Strtuhers A.D. C-type natriuretic peptide. Peptides 17 (1996) 1243-1251
20. Scotland R.S., Ahluwalia A., and Hobbs A.J. C-type natriuretic peptide in vascular physiology and disease. Pharm Ther 105 (2005) 85-93
21. Barton M., Beny J.L., d'Uscio L.V., Wyss T., Noll G., and Luscher T.F. Endothelium-independent relaxation and hyperpolarization to C-type natriuretic peptide in porcine coronary arteries. J Cardiovasc Pharmacol 31 3 (1998) 377-383
22. Chauhan S.D., Nilsson H., Ahluwalia A., and Hobbs A.J. Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. PNAS 100 (2003) 1426-1431
23. Griffith T.M. Endothelium-dependent smooth muscle hyperpolarization: do gap junctions provide a unifying hypothesis?. Br J Pharm 141 (2004) 881-903
24. Komatsu J.B., Nakao K., Suga S., Ogawa Y., Mukoyama M., Arai H., et al. C-type natriuretic peptide (CNP) in rats and humans. Endocrinology 129 (1991) 1104-1106
25. Ueda S., Minamino N., Aburaya M., Kangawa K., Matsukura S., and Matsuo H. Distribution and characterization of immunoreactive porcine C-type natriuretic peptide. Biochem Biophys Res Commun 175 (1991) 759-767
26. Vollmar A.M., Gerbes A.L., Nemer M., and Schulz R. Detection of C-type natriuretic peptide (CNP) transcript in the rat heart and immune organs. Endocrinology 134 4 (1993) 1872-1874
27. Schiller P.W., Bellini F., Dionne G., Maziak L.A., Garcia R., De Lean A., et al. Synthesis and activity profiles of atrial natriuretic peptide (ANP) analogs with reduced ring size. Biochem Biophys Res Commun 138 (1986) 880-886
28. Furuya M., Tawaragi Y., Minamitake Y., Kitajima Y., Fuchimura K., Tanaka S., et al. Structural requirements of C-type natriuretic peptide for elevation of cyclic GMP in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 183 (1992) 964-969
29. Takei Y. Does the natriuretic peptide system exist throughout the animal and plant kingdom?. Comp Biochem Physiol B: Biochem Mol Biol 129 (2001) 559-573
30. Samson W.K. Natriuretic peptides: a family of hormones. Trend Endocrinol Metab 3 (1992) 86-90
31. Kalra P.R., Anker S.D., Struthers A.D., and Coats A.J.S. The role of C-type natriuretic peptide in cardiovascular medicine. Eur Heart J 22 (2001) 997-1007
32. Fowkes R.C., and McArdle C.A. C-type natriuretic peptide: an important neuroendocrine regulator?. TEM 11 (2000) 333-338
33. Wu C., Wu F., Pan J., Morser J., and Wu Q. Furin-mediated processing of pro-C-type natriuretic peptide. J Biol Chem 278 (2003) 25847-25852
34. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3 (2002) 753-766
35. Tawaragi Y., Fuchimura K., Tanaka S., Minamino N., Kangawa K., and Matsuo H. Gene and precursor structures of human C-type natriuretic peptide. Biochem Biophys Res Commun 175 (1991) 645-651
36. Stingo A.J., Clavell A., Heublein D.M., Wei C.M., Pittelkow M.R., and Burnett J.C. Presence of C-type natriuretic peptide in cultured human endothelia cells and human plasma. Am J Physiol 263 (1992) H1318-H1321
37. Togashi K., Kameya T., Kurosawa T., Hasegawa N., and Kawakami M. Concentrations and molecular forms of C-type natriuretic peptide in brain and cerebrospinal fluid. Clin Chem 38 (1992) 2136-2139
38. Totsune K., Takahashi K., Ohneda M., Itoi K., Murakami O., and Mouri T. C-type natriuretic peptide in the human central nervous system: distribution and molecular form. Peptides 15 (1994) 37-40
39. Mattingly M.T., Brandt R.R., Heublein D.M., Wei C., Nir A., and Burnett J.C. Presence of C-type natriuretic peptide in human kidney and urine. Kidney Int 46 (1994) 744-747
40. Zhihong Y., and Luscher T. Vascular endothelium. In: Lanzer P., and Topol J.E. (Eds). Pan vascular medicine. Integrated clinical management (2002), Springer
41. Suga S., Nakao K., Ithoh H., Komatsu Y., Ogawa Y., Hama N., et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-β. Possible existence of "vascular natriuretic peptide system". J Clin Invest 90 (1992) 1145-1149
42. Suga S., Ithoh H., Komatsu Y., Ogawa Y., Hama N., Yoshimasa T., et al. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells-evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology 133 (1993) 3038-3041
43. Mantovani A., Bussolino F., and Dejana E. Cytokine regulation of endothelial function. FASEB J 6 (1992) 2591-2599
44. Ross R. Polypeptide growth factors and atherosclerosis. Trends Cardiovasc Med 1 (1991) 277-282
45. Nazario B., Hu R., Pedram A., Bruce P., and Levin E.R. Atrial and brain natriuretic peptides stimulate the production and secretion of C-type natriuretic peptide from bovine aortic endothelial cells. J Clin Invest 95 (1995) 1151-1157
46. Suga S., Nakao K., Hosoda K., Mukoyama M., Ogawa Y., Shirakami G., et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic. Endocrinology 130 (1992) 229-239
47. Koller K.J., Love D.G., Bennett G.L., Minamino N., Kangawa K., Matsuo H., et al. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science 252 (1991) 120-123
48. Maack T., Suzuki M., Almeida F.A., Nussenzveig D., Scarborough R.M., McEnroe G.A., et al. Physiological role of silent receptors of atrial natriuretic factor. Science 238 (1987) 675-678
49. Kenny A., Bourne A., and Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 291 (1993) 83-88
50. Brandt R.R., Mattingly M.T., Clavell A.L., Barclay P.L., and Burnett J.C. Neutral endopeptidase regulates C-type natriuretic peptide metabolism but does not potentiate its bioactivity in vivo. Hypertension 30 (1997) 184-190
51. Chinkers M., and Gabers D.L. The protein kinase domain of the ANP receptor is required for signaling. Science 245 (1989) 1392-1394
52. Komatsu Y., Nakao K., Itoh H., Suga S., Ogawa Y., and Imura H. Vascular natriuretic peptide. Lancet 34 (1992) 622
53. Nunez D.J.R., Ickson C.M., and Brown K.J. Natriuretic peptide receptor mRNAs in the rat and human heart. J Clin Invest 90 (1992) 1966-1971
54. Wei C.M., Heublein D.M., Perella M.A., Lerman A., Rodeheffer R.J., McGregor C.G., et al. Natriuretic peptide system in human heart failure. Circulation 88 (1993) 1004-1009
55. Steinmetz M., Potthast R., Sabrane K., and Kuhn M. Diverging vasorelaxing effects of C-type natriuretic peptide in renal resistance arteries and aortas of GC-A-deficient mice. Regul Pept 119 (2004) 31-37
56. Ahluwalia A., and Hobbs A.J. Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarizing factor. Trends Pharmacol Sci 26 (2005) 162-167
57. Klinger J.R., Siddiq F.M., Swift R.A., Jackson C., Pietras L., Warburton R.R., et al. C-type natriuretic peptide expression and pulmonary vasodilation in hypoxia-adapted rats. Am J Physiol 19 (1998) L645-L652
58. Mitani Y., Maruyama J., Yokochi A., Maruyama K., Yoshimoto T., Naruse M., et al. Modulated vasodilator responses to natriuretic peptides in rats exposed to chronic hypoxia. Eur Respir J 15 (2000) 400-406
59. Komatsu Y., Itoh H., Suga S., Ogawa Y., Hama N., Kishimoto I., et al. Regulation of endothelial production of C-type natriuretic peptide in coculture with vascular smooth muscle cells: role of the vascular natriuretic peptide system in vascular growth inhibition. Circ Res 78 (1996) 606-614
60. Qian J.Y., Haruno A., Asada Y., Nishida T., Saito Y., Matsuda T., et al. Local expression of C-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ Res 91 (2002) 1063-1069
61. Richards A.M. Outpatient management of heart failure. Heart Fail Rev 8 (2003) 345-348
62. Richards A.M. The natriuretic peptides in heart failure. Basic Res Cardiol 99 (2004) 94-100
63. Jortani S.A., Prabhu S., and Valdes R.V. Strategies for developing biomarkers of heart failure. Clin Chem 50 (2004) 265-278
64. Totsune K., Takahashi K., Murakami O., Satoh F., Sone M., and Mouri T. Elevated plasma C-type natriuretic peptide concentrations in patients with chronic renal failure. Clin Sci 87 (1994) 319-322
65. Cargill R.I., Barr C.S., Coutie W.J., Struthers A.D., and Lipworth B.J. C-type natriuretic peptide levels in cor pulmonare and in congestive cardiac failure. Thorax 49 (1994) 1247-1249
66. Del Ry S., Passino C., Maltinti M., Emdin M., and Giannessi D. C-type natriuretic peptide plasma levels increase in patients with congestive heart failure as a function of clinical severity. Eur J Heart Fail 7 (2005) 1145-1148
67. Del Ry S., Maltinti M., Emdin M., Passino C., Catapano G., and Giannessi D. Radioimmunoassay for plasma C-type natriuretic peptide determination: a methodological evaluation. Clin Chem Lab Med 43 (2005) 641-645
68. 2+-ATPase gene. Circ Res 71 (1992) 9-17
69. Stepan H., Leitner E., Bader M., and Walther T. Organ specific mRNA distribution of C-type natriuretic peptide in neonatal and adult mice regulatory. Peptides 95 (2000) 81-85
70. Kalra P.R., Clague J.R., Bolger A.P., Anker S.D., Poole-Wilson P.A., Struthers A.D., et al. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 107 (2003) 571-573
71. Del Ry S., Maltinti M., Piacenti M., Passino C., Emdin M., and Giannessi D. Cardiac production of C-type natriuretic peptide in heart failure. J Cardiovasc Med 7 (2006) 397-399
72. Horio T., Tokudome T., Maki T., Yoshihara F., Suga S., Nishikimi T., et al. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblast. Endocrinology 144 (2003) 2279-2284
73. Tokudome T., Horio T., Soeki T., Mori K., Kishimoto I., Suga S., et al. Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: interference between CNP and endothelin-1 signaling pathways. Endocrinology 145 (2004) 2131-2140
74. Prickett T.C.R., Yandle T.G., Nicholls M.G., Espiner E.A., and Richards A.M. Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochem Biophys Res Commun 286 (2001) 513-517
75. Wright S.P., Prickett T.C., Doughty R.N., Frampton C., Gamble G.D., Yandle T.G., et al. Amino-terminal pro-C-type natriuretic peptide in heart failure. Hypertension 43 (2004) 94-100
76. Chen H.H., and Burnett J.C. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 32 (1998) S22-S28
77. Potter L.R. CNP, cardiac natriuretic peptide?. Endocrinology 145 5 (2004) 2129-2130
78. Charles C.J., Espiner E.A., Richards A.M., Nicholls M.G., and Yandle T.G. Comparative bioactivity of atrial, brain and C-type natriuretic peptides in conscious sheep. Am J Physiol 270 (1996) R1324-R1331
79. Margulies K.B., Perella M.A., McKinlay L.J., and Burnett J.C. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 88 (1991) 1636-1642
80. Cruden N.L., Fox K.A., Ludlam C.A., Johnston N.R., and Newby D.E. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension 44 (2004) 913-918
81. Abassi Z.A., Yahia A., Zeid S., Karram T., Golomb E., Winaver J., et al. Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure. Am J Physiol Heart Circ Physiol 288 (2005) H722-H728
82. Emoto N., Raharjo S.B., Isaka D., Masuda S., Adiarto S., Jeng A.Y., et al. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 45 (2005) 1145-1152
83. Solomon S.D., Skali H., Bourgoun M., Fang J., Ghali J.K., Martelet M., et al. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE) echocardiographic study. Am Heart J 150 (2005) 257-262
84. Mellin V., Jeng A.Y., Monteil C., Rennet S., Henry J.P., Thuillez C., et al. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition. J Cardiovasc Pharmacol 46 (2005) 390-397
85. Fitzgerald R.L., Cremo R., Gardetto N., Chiu A., Clopton P., Bhalla V., et al. Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Am Heart J 150 (2005) 471-477
86. Burger A.J., and Burger M.R. Nesiritide: past, present, and future. Minerva Cardioangiol 53 (2005) 509-522
87. Sackner-Berstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
88. Sackner-Berstein J.D., Kowalsaki M., Fox M., and Aaronson K.D. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905